⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
globenewswire.com
CRNX
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity USA - English USA - English
prnewswire.com
VEEV
BMY
MRNA
NVO
OTK
CRNX
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity USA - English USA - English
prnewswire.com
VEEV
BMY
MRNA
NVO
OTK
CRNX
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
globenewswire.com
CRNX